News
Investing.com -- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) stock surged 19% after the company announced FDA approval of EKTERLY (sebetralstat), the first and only oral on-demand treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback